Literature DB >> 15323464

Principles and techniques of en bloc vertebrectomy for bone tumors of the thoracolumbar spine: an overview.

Robert J Bohinski1, Laurence D Rhines.   

Abstract

Oncological principles for en bloc resection of bone tumors were initially developed for tumors of the long bone by orthopedic surgical oncologists. Recently, spine surgeons have adopted these principles for the treatment of vertebral column tumors. The goal of en bloc resection is to establish a surgical margin that can be designated marginal or wide. In this article, the principles of surgical oncology for bone tumors of the spine are briefly reviewed and the different surgical approaches used to remove these tumors in an en bloc fashion are described in detail.

Entities:  

Mesh:

Year:  2003        PMID: 15323464     DOI: 10.3171/foc.2003.15.5.7

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  4 in total

1.  [Surgical technique of en bloc spondylectomy for solitary metastases of the thoracolumbar spine].

Authors:  A C Disch; I Melcher; A Luzatti; N P Haas; K-D Schaser
Journal:  Unfallchirurg       Date:  2007-02       Impact factor: 1.000

2.  Spinal cord compression.

Authors:  Eduardo Santamaria Carvalhal Ribas; David Schiff
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

3.  Analysis of the spinal nerve roots in relation to the adjacent vertebral bodies with respect to a posterolateral vertebral body replacement procedure.

Authors:  Waleed Awwad; Jonathan Bourget-Murray; Nadil Zeiadin; Juan P Mejia; Thomas Steffen; Abdulrahman D Algarni; Khalid Alsaleh; Jean Ouellet; Michael Weber; Peter F Jarzem
Journal:  J Craniovertebr Junction Spine       Date:  2017 Jan-Mar

4.  Evaluation of parallel endplate osteotomy for severe rigid spinal deformities: a retrospective analysis of 36 cases with a minimum 2-year follow-up.

Authors:  Hang Liao; Peng Xie; Guizhou Zheng; Houguang Miao; Ningdao Li; Xuedong Li; Shixin Du
Journal:  BMC Musculoskelet Disord       Date:  2021-12-03       Impact factor: 2.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.